Opening Global Access to Advanced Therapies
REALM Bio
To maintain viability, autologous cells collected from patients must typically reach a manufacturing site within 24 hours.
A Disparity in Access
In 2022 the World Economic Forum reported that approximately 1,000 open gene therapy clinical trials were underway globally, but fewer than 5% were recruiting in low- and middle-income countries (excluding China), with only four trials taking place in Africa. It’s a disparity that continues today.
Imagine a world where life-changing cell and gene therapies are within everyone’s reach – where the power to heal isn’t limited by geography or circumstance.
At REALM Bio, we’re working to bring these groundbreaking treatments to underserved communities around the world and right here at home – because no one should be beyond reach.
REALM Bio Erases the Gap
With decades of expertise in global clinical logistics and operations, REALM Bio proudly introduces the 1REALM Unified Services Platform.
This groundbreaking initiative actively breaks down barriers to make advanced therapies universally accessible, transcending economic and geographic limitations.